"Psilocybin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major of two hallucinogenic components of Teonanacatl, the sacred mushroom of Mexico, the other component being psilocin. (From Merck Index, 11th ed)
| Descriptor ID |
D011562
|
| MeSH Number(s) |
D03.132.436.613 D03.633.100.473.402.613 D03.633.100.473.914.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Psilocybin".
Below are MeSH descriptors whose meaning is more specific than "Psilocybin".
This graph shows the total number of publications written about "Psilocybin" by people in this website by year, and whether "Psilocybin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 2 | 3 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psilocybin" by people in Profiles.
-
Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. 2026 Sep 03; 393(6815):eaec6116.
-
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence. Neuropsychopharmacology. 2026 Jun; 51(7):1310-1324.
-
From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care. Transl Behav Med. 2026 Jan 07; 16(1).
-
Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with obsessive-compulsive disorder: international findings from the LATINO Study. Braz J Psychiatry. 2026; 48:e20254316.
-
A landscape analysis of psychedelic retreat organizations advertising online. PLoS One. 2025; 20(5):e0321648.
-
Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use. J Psychoactive Drugs. 2026 Jul-Aug; 58(3):286-297.
-
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep. 2024 11 14; 14(1):28022.
-
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024 05; 335:115886.
-
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology. 2022 11 15; 219:109214.